Adaptive study of IL-2 dose on regulatory T cells in Type 1 Diabetes (DILT1D)
Phase of Trial: Phase I/II
Latest Information Update: 01 Oct 2016
At a glance
- Drugs Aldesleukin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms DILT1D
- 10 Jun 2017 Biomarkers information updated
- 13 Jun 2014 Status changed from recruiting to completed as reported by United Kingdom Clinical Research Network record.
- 11 Apr 2014 Accrual to date is 115% according to United Kingdom Clinical Research Network record.